Irofulven

Summary

Irofulven (CHEMBL118218) is a phase-3 clinical-stage small molecule; indicated across 19 conditions including exocrine pancreatic carcinoma and cutaneous melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 19 conditions
• Clinical trials: 20
• Chemistry: 246.3 Da · C15H18O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL118218
Name	Irofulven
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	148189
Molecular formula	C15H18O3
Molecular weight	246.3
InChIKey	NICJCIQSJJKZAH-AWEZNQCLSA-N

SMILES: CC1=C(C2=C(C3(CC3)[C@@](C(=O)C2=C1)(C)O)C)CO

IUPAC name: (5’R)-5’-hydroxy-1’-(hydroxymethyl)-2’,5’,7’-trimethylspiro[cyclopropane-1,6’-indene]-4’-one

Also known as: (hydroxymethyl)acylfulvene, Irofulven, Irofulvene, Irofulveno, LP-100, MGI 114, MGI-114, MGI114, NSC-683863, (-)-(hydroxymethyl)-acylfulvene, irofulven, (Hydroxymethyl)acylfulvene

Patent coverage: 1,878 distinct patent families (7,582 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin reductase 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P97584	7.26	IC50	55	nM	CHEMBL_ACT_1702315

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

15 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
kidney cancer	2	MONDO:0002367	MONDO:0002367
breast neoplasm	2	MONDO:0021100	MONDO:0007254
ovarian cancer	2	MONDO:0008170	MONDO:0008170
lung neoplasm	2	MONDO:0021117	MONDO:0008903
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
neoplasm	1	MONDO:0005070	EFO:0000616
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198
leukemia	1	MONDO:0005059	EFO:0000565
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE2	15
PHASE1/PHASE2	2
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00033735	PHASE3	COMPLETED	Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
NCT00003390	PHASE2	COMPLETED	6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
NCT00003441	PHASE2	COMPLETED	Irofulven in Treating Patients With Metastatic Colorectal Cancer
NCT00003666	PHASE2	COMPLETED	Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
NCT00003760	PHASE2	COMPLETED	Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
NCT00003786	PHASE2	WITHDRAWN	Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00003796	PHASE2	COMPLETED	Irofulven in Treating Patients With Metastatic Breast Cancer
NCT00005031	PHASE2	COMPLETED	Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
NCT00005070	PHASE2	COMPLETED	Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer
NCT00005968	PHASE2	COMPLETED	Irofulven in Treating Patients With Stage IV Melanoma
NCT00012038	PHASE1/PHASE2	COMPLETED	Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
NCT00019552	PHASE2	COMPLETED	Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00053365	PHASE2	COMPLETED	Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00062257	PHASE2	COMPLETED	Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer
NCT00124527	PHASE2	COMPLETED	Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
NCT00124566	PHASE2	COMPLETED	Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
NCT00374660	PHASE1/PHASE2	COMPLETED	Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
NCT03643107	PHASE2	COMPLETED	Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
NCT00003370	PHASE1	COMPLETED	Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
NCT00003997	PHASE1	COMPLETED	6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).